Investigating kidney cell regeneration in nephropathy
Studying the Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases: Analysis on Renal Biopsies
This study is testing how certain kidney cells can help repair damage in people with kidney disease and acute kidney injury.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 1 Month to 17 Years |
| Sex | All |
| Sponsor | Meyer Children's Hospital IRCCS Academic / other |
| Locations | 1 site (Florence) |
| Trial ID | NCT06325059 on ClinicalTrials.gov |
What this trial studies
This study explores the role of renal progenitor cells and polyploid tubular cells in the context of glomerular and tubular diseases, particularly nephropathy. It focuses on how these cells can potentially regenerate lost podocytes and respond to damage during acute kidney injury. By examining patients undergoing renal biopsy for various glomerular diseases and those with acute kidney injury, the study aims to understand the mechanisms behind kidney cell regeneration and their implications for chronic kidney disease progression.
Who should consider this trial
Good fit: Ideal candidates include patients with glomerular diseases requiring renal biopsy and those experiencing acute kidney injury.
Not a fit: Patients with insufficient or unavailable biopsy samples will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies for kidney diseases, improving patient outcomes and slowing the progression of chronic kidney disease.
How similar studies have performed: While the specific approach of this study is novel, similar studies have shown promise in understanding kidney cell regeneration.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with glomerular diseases undergoing renal biopsy (e.g., rapidly progressive glomerulonephritis, minimal change disease, focal segmental glomerulosclerosis, diabetic nephropathy, lupus nephritis, membranous nephropathy, IgA nephropathy, etc) * Patients with AKI, regardless of the nature of the damage (septal, ischemic, toxic, or unknown). * Signed informed consent form Exclusion Criteria: * Sample insufficient and/or unavailable
Where this trial is running
Florence
- Meyer Children's Hospital IRCCS — Florence, Italy (Recruiting)
Study contacts
- Study coordinator: Paola Romagnani, MD
- Email: paola.romagnani@meyer.it
- Phone: 055 5662562
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.